Saturday 17 October 2026
Export EXOZ’s income statement to Excel — free account
eXoZymes Inc.
EXOZ Healthcare Biotechnology
eXoZymes Inc.’s revenue for fiscal 2023 (year ended December 2023) was $70,100.00. In the quarter to June 2026, EPS fell 17.9%, free cash flow fell 3.25% and total debt fell 52.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.09
0.09
+2.25%
Follow EXOZ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (187.16%) | (185.84%) | (132.56%) | (940.69%) |
+7 more TTM periods Free account |
|
| (115.42%) | (124.45%) | (96.38%) | (147.87%) | ||
ROIC |
0.00% | (4,655.49%) | (1,438.02%) | (1,597.40%) | |
Return on Tangible Assets |
(195.16%) | (770.41%) | (291.95%) | (162.55%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.82) | (0.84) | (0.80) | (1.26) | |
Free Cash Flow |
(7.14) | (7.09) | (6.67) | (10.54) | |
Capital Expenditures |
(0.15) | (0.20) | (0.17) | (0.31) | |
| Other line items | |||||
Cash ROIC |
(76.39%) | (234.32%) | (102.63%) | (99.92%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.69 | 0.71 | 0.71 | 1.23 | |
Depreciation/Fixed assets |
0.37 | 0.32 | 0.31 | 0.30 | |
Capex/Depreciation |
(0.59) | (0.82) | (0.72) | (1.34) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.81) | (0.81) | (0.78) | (1.22) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates